Literature DB >> 19942636

Evidence of vasopressinergic-noradrenergic mechanisms in depression with above-normal plasma vasopressin concentration with and without psychotic features.

Jaap G Goekoop1, Remco F P de Winter, Ron Wolterbeek, Godfried M J van Kempen, Victor M Wiegant.   

Abstract

Previous studies in the field of melancholic or endogenous depression have resulted in support for a subcategory of depression with above-normal plasma vasopressin (AVP) concentration (ANA). Since an analogous animal model with increased release of above-normal plasma vasopressin exhibits reduced Sympathetic-Nervous-System activity, the present study investigated the plasma norepinephrine concentration and the correlation between plasma norepinephrine and AVP in this ANA depression. As psychotic-melancholic patients may have increased plasma norepinephrine concentration, and noradrenergic activation may stimulate AVP release, potentially confounding effects of psychotic features were also investigated. The data set of the same depressed patient sample that was used before, but limited to those with complete hormonal data (n = 75), was re-analysed. ANA depression (n = 14) had negatively correlating AVP and norepinephrine concentrations. A very small subcategory of ANA depression with psychotic features (n = 3) had high plasma norepinephrine concentration, suggesting that this could be an independent subcategory. This was supported by the combination of relatively low above-normal plasma AVP concentrations with the highest severity scores for depression in this subcategory, which does not correspond with the positive correlation between AVP concentration and severity in non-psychotic ANA depression. The results further support the validity of ANA depression and the analogy with the High Anxiety Behaviour animal model of depression. Further investigations are needed to replicate these findings and to search for genetic and traumatic factors involved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942636     DOI: 10.1177/0269881109349839

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  4 in total

1.  Increased plasma norepinephrine concentration in psychotic depression.

Authors:  Jaap G Goekoop; Remco F P de Winter; Ron Wolterbeek; Godfried M J Van Kempen; Victor M Wiegant
Journal:  Ther Adv Psychopharmacol       Date:  2012-04

2.  Temperament and character in psychotic depression compared with other subcategories of depression and normal controls.

Authors:  Jaap G Goekoop; Remco F P De Winter
Journal:  Depress Res Treat       Date:  2011-11-22

3.  Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study.

Authors:  Agorastos Agorastos; Anne Sommer; Alexandra Heinig; Klaus Wiedemann; Cüneyt Demiralay
Journal:  Front Psychiatry       Date:  2020-05-20       Impact factor: 4.157

Review 4.  Is Oxytocin "Nature's Medicine"?

Authors:  C Sue Carter; William M Kenkel; Evan L MacLean; Steven R Wilson; Allison M Perkeybile; Jason R Yee; Craig F Ferris; Hossein P Nazarloo; Stephen W Porges; John M Davis; Jessica J Connelly; Marcy A Kingsbury
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.